Dexcom puts up new data in Type 2 diabetes, teases upcoming G7 sensor

FIERCEBIOTECH, 07/06/2021

Partagé par : 

Beesens TEAM

Dexcom puts up new data in Type 2 diabetes, teases upcoming G7 sensor

"To follow up on what it’s described as its “best year ever,” Dexcom has accelerated the development of the newest version of its mainstay continuous glucose monitor in 2021—and delivered new clinical data showing CGM systems can provide significant benefits to patients with Type 2 diabetes, which the company has pegged as a major growth market.
During the International Conference on Advanced Technologies and Treatments for Diabetes, Dexcom delivered its first randomized, controlled study showing people with Type 2 diabetes using background insulin could benefit from real-time blood sugar data and see strong reductions in A1c and hyperglycemia.

Published in JAMA, the study found participants using Dexcom’s current G6 sensor spent nearly four more hours each day within an optimal glucose range and experienced fewer periods of low blood sugar compared to people using traditional fingerstick monitors.

In addition, by employing CGM and Dexcom’s software to help guide therapies and lifestyle changes, the study’s 175 users demonstrated an average drop in HbA1c of 0.4 percentage points over eight months, with clinical benefits seen across all patient demographics regardless of age, education, math skills or socioeconomic status, according to Dexcom’s vice president of medical affairs, David Price, M.D.

Type 2 diabetes patients represent a large market—including those who are and are not receiving intensive insulin therapies—and serve as a main pillar of the company’s growth strategy for this year..." Lire la suite